Specifically, agonists of PXR that are semisynthetic derivatives of rifamycin (for example, rifaximin and rifampicin) have been studied for the treatment of IBD in clinical trials, and decreased PXR expression has been associated with IBD and CD4,38,39,42–46. Here, NR1I2 is linked to inflammatory bowel disease.